Skip to Content

Notice

Bulk Manufacturer of Controlled Substances Application: Noramco, Inc.

This document has a comment period that ends in 50 days. (07/21/2020) Submit a formal comment

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of application.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 21, 2020.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on February 26, 2020, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801-4417, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substanceDrug codeSchedule
Marihuana7360I
Tetrahydrocannabinols7370I
Codeine-N-oxide9053I
Dihydromorphine9145I
Hydromorphinol9301I
Morphine-N-oxide9307I
Amphetamine1100II
Lisdexamfetamine1205II
Methylphenidate1724II
Nabilone7379II
Phenylacetone8501II
Codeine9050II
Dihydrocodeine9120II
Oxycodone9143II
Hydromorphone9150II
Hydrocodone9193II
Morphine9300II
Oripavine9330II
Thebaine9333II
Opium extracts9610II
Opium fluid extract9620II
Opium tincture9630II
Opium, powdered9639II
Opium, granulated9640II
Oxymorphone9652II
Noroxymorphone9668II
Tapentadol9780II

The company plans to manufacture the listed controlled substances as an Active Pharmaceutical Ingredient (API) for supply to its customers. In reference to drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drug codes are authorized for this registration. This notice does not constitute an evaluation or determination of the merits of the company's application.

Start Signature

William T. McDermott,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2020-11077 Filed 5-21-20; 8:45 am]

BILLING CODE 4410-09-P